Core Viewpoint - UnitedHealth Group's subsidiary, UnitedHealthcare, has secured a contract from the State of Kansas to provide services for the Medicaid and Children's Health Insurance Program, effective from early 2025, which is expected to enhance health outcomes for members through collaboration with local providers and organizations [1][2]. Group 1: Contract and Membership Impact - The renewal of the KanCare contract is attributed to UnitedHealthcare's extensive experience of over a decade serving its members, which is likely to expand its customer base and increase premiums, significantly contributing to revenue growth [2]. - As of March 31, 2024, UnitedHealthcare's Medicaid membership stood at 7.7 million, with overall premiums for UnitedHealth Group increasing by 7.1% year over year in the first quarter [2][3]. - The contract win is expected to strengthen UnitedHealth Group's presence in Kansas, where it already has a substantial membership base and provider network [2]. Group 2: Operational Network and Strength - UnitedHealthcare operates a network of 150 hospitals and over 22,000 physicians and care providers in Kansas, serving more than 570,000 residents across various benefit plans [3]. - The strength of UnitedHealthcare's Medicaid business, bolstered by community partnerships and investments, has led to multiple contract wins, including being one of three managed care organizations selected for the KanCare contract [3]. Group 3: Stock Performance - UnitedHealth Group's shares have increased by 4% over the past month, outperforming the industry growth of 3.3% [4].

Company Overview - UnitedHealth Group Incorporated (UNH) is the largest player in the health insurance industry, with a market capitalization exceeding that of all its publicly listed competitors combined [3] - The company operates in a sector expected to grow significantly due to an aging global population and increasing rates of chronic diseases, with the global health insurance market projected to grow from $1.8 trillion in 2024 to $3.2 trillion by 2032, representing a compound annual growth rate of 6.2% [3] Financial Performance - In Q1 2024, UNH reported total revenues of $99.8 billion, an increase of 8.6% year-over-year, surpassing analyst expectations by $490 million [7] - The company has consistently exceeded analyst consensus for revenue and non-GAAP EPS, achieving revenue beats in 17 of the last 19 quarters and non-GAAP EPS beats in all 19 quarters leading up to Q1 2024 [7] - Adjusted diluted EPS for Q1 2024 was $6.91, reflecting a 10.4% increase from the previous year and exceeding analyst consensus by $0.29 [11] Membership and Market Segments - Total medical membership declined by 2.7% to 51.5 million, primarily due to the sale of its Brazil operations and increased redeterminations in Medicaid [9] - Domestic commercial members increased by 2.1 million, and Medicare Advantage membership rose by 2.8% to 7.8 million [10] - The number of people served through UnitedHealthcare's domestic commercial offerings and Medicare Advantage contributed to revenue growth, despite declines in global membership [8] Growth Projections - Analysts project adjusted diluted EPS to rise by 10.5% in 2024 to $27.75, with further increases anticipated in 2025 and 2026 [12] - The company's annual growth consensus is 12.2% for the next three years, supported by steady revenue growth and share buybacks [13] Valuation and Dividend Growth - UNH shares are currently trading at a P/E ratio of 18.6, below the 10-year normal P/E ratio of 20.2, suggesting potential for price appreciation [13] - The company has a five-year compound annual growth rate of dividends at 15.9%, significantly higher than the healthcare sector median of 6.6% [14] - A projected 13.3% increase in the quarterly dividend per share to $2.13 is anticipated, maintaining a sustainable payout ratio [14]

Core Viewpoint - UnitedHealth Group (UNH) is currently rated as a STRONG BUY by Wall Street analysts, with a score of 4.55, reflecting strong sentiment and confidence in the stock's long-term earning power and reasonable valuation following recent price corrections [3][4]. Analyst Ratings - Out of 27 analysts, 17 recommend Strong Buy, 8 recommend Buy, 2 recommend Hold, and none recommend Sell or Strong Sell, indicating a predominantly positive outlook [3]. Earnings Outlook - Analysts project a steady EPS growth for UNH at a CAGR of 9.5% over the next decade, supported by the company's scale and differentiated business model, particularly its vertical integration and data-driven approach [5][10]. Valuation Metrics - UNH is currently trading at a forward P/E of 18.8x, which is approximately 6% lower than the sector median of 19.9x and about 7% lower than its 5-year average P/E of 20.2x, suggesting a slight discount in valuation [7][8]. Cash Flow Analysis - The two-stage discounted free cash flow model estimates UNH's fair price at around $766 per share, compared to its current price of $581, indicating a significant margin of safety [12][16]. Medical Cost Ratio - By the end of 2023, UNH's medical cost ratio averaged 83.2%, up from 82.0% the previous year, with a peak of 85.0% in December, attributed to increased insurance usage as the pandemic recedes [4][10]. Competitive Advantages - UNH's competitive edge lies in its vertical integration and investment in technology and data analytics, which enhance care coordination and optimize health outcomes, positioning the company favorably in the evolving healthcare landscape [5][10]. Future Growth Projections - The projected free cash flow per share is expected to grow from $27.60 in 2023 to $68.40 by 2032, reflecting a robust growth trajectory [16].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of UnitedHealth Group Inc. regarding a class action lawsuit alleging that the company failed to establish proper firewalls between its businesses, Optum and UnitedHealthcare, leading to the sharing of sensitive customer information [1][2]. Group 1: Allegations and Class Action Details - The class period for the allegations is from March 14, 2022, to February 27, 2024 [1]. - The complaint claims that UnitedHealth made false statements and concealed the lack of meaningful technological separation between Optum and UnitedHealthcare, contrary to its own policies and assurances given to the court and investors [1]. - Shareholders are encouraged to register for the class action by July 15, 2024, to potentially be appointed as lead plaintiffs [2]. Group 2: Next Steps for Shareholders - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - There is no cost or obligation for shareholders to participate in the class action [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - The investigation by Moore Law, PLLC into UnitedHealth Group, Inc. centers on potential claims related to insider trading and antitrust violations stemming from the company's acquisition of Change Healthcare [2][3]. Group 1: Antitrust Investigation - The U.S. Department of Justice (DOJ) filed a lawsuit on February 24, 2022, challenging UnitedHealth's acquisition of Change Healthcare, alleging it would violate antitrust laws [2]. - On February 27, 2024, the Wall Street Journal reported that the DOJ re-opened its antitrust investigation into UnitedHealth, focusing on the relationships between the company's various segments, including Optum [2]. Group 2: Insider Trading Allegations - UnitedHealth was aware of the DOJ investigation since at least October 2023 but did not disclose this information to investors, leading to significant insider selling [3]. - Insiders sold over $120 million of their UnitedHealth shares, with Chairman Stephen Hemsley selling over $102 million and CEO Brian Thompson selling over $15 million [3]. Group 3: Whistleblower Program - The SEC Whistleblower program allows whistleblowers to receive rewards of up to 30 percent of any successful recovery made by the SEC for providing original information [3].

Company Performance - UnitedHealth Group (UNH) ended the latest trading session at $517.23, reflecting a -1.41% adjustment from the previous day's close [1] - The stock has gained 4.69% over the past month, underperforming the Medical sector's gain of 5.88% and the S&P 500's gain of 5.78% [1] - The upcoming earnings release is expected to show an EPS of $6.76, indicating a 10.1% growth year-over-year, with revenue projected at $98.88 billion, a 6.44% increase compared to the same quarter last year [1] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $27.60 per share and revenue at $398.1 billion, representing changes of +9.87% and +7.13% from the prior year [2] - Recent adjustments to analyst estimates reflect short-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [2] Zacks Rank and Valuation - UnitedHealth Group currently holds a Zacks Rank of 3 (Hold), with a recent 0.42% decline in the Zacks Consensus EPS estimate [3] - The company is trading at a Forward P/E ratio of 19.01, which is a premium compared to the industry average of 16.19 [3] - The PEG ratio for UNH is 1.52, compared to the Medical - HMOs industry average PEG ratio of 1.18 [3] Industry Overview - The Medical - HMOs industry is part of the Medical sector and currently holds a Zacks Industry Rank of 71, placing it in the top 29% of over 250 industries [4] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]

Core Viewpoint - UnitedHealth Group is benefiting from an expanding premium base, contract wins, strength in the Optum business, and a solid financial position, with an optimistic earnings outlook for 2024 reinforcing investor confidence in the stock [1] Financial Performance - UnitedHealth Group currently has a Zacks Rank of 3 (Hold) and has gained 9.2% over the past year, slightly outperforming the industry growth of 9.1% [2] - The Zacks Consensus Estimate for 2024 earnings is $27.60 per share, reflecting a 9.9% increase from the previous year, with revenues expected to reach $398.1 billion, indicating a 7.1% growth [4] - The consensus estimate for 2025 earnings is $30.98 per share, suggesting a 12.3% growth from 2024, with revenues projected at $426.5 billion, also a 7.1% increase [4] - UnitedHealth Group has a return on equity of 26.5%, surpassing the industry average of 23.8%, demonstrating efficient use of shareholders' funds [6] Business Growth Drivers - The company is experiencing revenue growth due to strong contributions from its UnitedHealthcare and Optum businesses, with effective Medicare and Medicaid plans expanding the membership base and increasing premiums [8] - The Optum unit is leveraging acquisitions and advanced technology, with plans to serve an additional 750,000 patients in value-based arrangements in 2024 [9] - UnitedHealth Group's solid financial position allows for strategic investments, including share buybacks and dividends, with a dividend yield of 1.4%, higher than the industry average of 1.3% [10] Earnings Surprise and Outlook - UnitedHealth Group has a strong earnings surprise history, exceeding estimates in the last four quarters with an average surprise of 3.65% [5] - Adjusted net earnings per share for 2024 are forecasted to be between $27.50 and $28.00, indicating a 10.5% improvement from 2023 [7]

Group 1 - ClaimsFiler reminds investors that they have until July 15, 2024, to file lead plaintiff applications in a securities class action lawsuit against UnitedHealth Group Inc. for shares purchased between March 14, 2022, and February 27, 2024 [1] - The lawsuit alleges that UnitedHealth and certain executives failed to disclose material information during the Class Period, violating federal securities laws [1] - The case is identified as City of Hollywood Firefighters' Pension Fund v. UnitedHealth Group Inc., No. 24-cv-1743 [2] Group 2 - On February 27, 2024, the U.S. Department of Justice re-opened its antitrust investigation into UnitedHealth's various segment relationships, leading to a share price drop of $27, erasing nearly $25 billion in shareholder value [2] - ClaimsFiler serves as a resource for retail investors to recover funds from securities class action settlements, offering free registration for access to information and case evaluations [2]

Group 1 - A class action lawsuit has been filed against UnitedHealth Group Inc. for alleged securities fraud and unlawful business practices [1] - The lawsuit allows shareholders who purchased UnitedHealth securities during the Class Period to seek appointment as Lead Plaintiff by July 15, 2024 [1] - The U.S. Department of Justice has initiated an antitrust investigation into UnitedHealth, focusing on its health services arm, Optum [2] Group 2 - Following the news of the antitrust investigation, UnitedHealth's stock price dropped by $27.04, or 5.15%, closing at $498.28 per share on February 28, 2024 [2] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having recovered billions in damages for class members [3]

A month has gone by since the last earnings report for UnitedHealth Group (UNH) . Shares have added about 8.1% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is UnitedHealth due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. UnitedHealth Group Tops on Q1 Earnings, Reaffi ...